3 ms·
This is the flip side of the brokenness of the patent system - even when it ends up working correctly to facilitate research, the results are still a horribly b
by mindslight 13y ago
This is the flip side of the brokenness of the patent system - even when it ends up working correctly to facilitate research, the results are still a horribly broken game that pits the drug maker directly against the general public interest.
Gilead needs some way to fund themselves, but long-shot lottery-like reimbursement based on a monopoly followed by the inevitable politicking to stop Gilead's "gouging" (of which this article is a part of) is not a good system for doing this.
Not that I think pure publicly-funded research is the way forward either, especially if we'd like to increase incentives for science. That current system works in spite of its brokenness only because the people who are there truly care about their work - scaling it up would be disastrous.
But, especially in this case where the boundaries of ownership arise out of no natural phenomenon, we really need to be smoothing out discontinuities, rather than exacerbating them with simplistic approaches and pretending that the betting wisdom of investors (who by construction are abstracted and out of touch from what's actually going on) will achieve the desired result.
- Houshalter 13y agoHow is the system broken? This drug wouldn't even exist if they weren't able to charge such a high price for it. And nothing is preventing the government or other organizations from also researching drugs. It's not mutually exclusive and it's unlikely two labs would discover the exact same drug.
- mindslight 13y agoThey're charging much more than the cost to develop the drug, because they need to pay for all of their failed attempts (and at this point, the only constraint is when the insurance companies will balk). And if they're able to charge this indefinitely, then they're effectively just extracting rent regardless of how much goes into further research (which you can say that they've earned the right to do this, but that's still what they're doing). I'm certainly not saying they shouldn't be compensated, but taking issue with they way they're compensated. As I said, the problem is that it's an extreme gamble, and the only thing this is conducive to is business gamers and the overhead and blindspots they bring. Since the current reimbursement mechanism completely relies on the utterly artificial construction of the patent system, it's reasonable to believe that the entire model could be redesigned.
- Houshalter 13y agoFailed drugs are part of the cost of getting working drugs. And it's not indefinitely - it's until the patent expires, or in this case until other treatments start getting on the market in a few years.
- mindslight 13y agoYou are nitpicking specifics that don't actually change what I'm saying while completely ignoring the crux of my point.
- Houshalter 13y agoWhat's the crux of your point? How would you prefer the system work? As I said, it's not mutually exclusive. You can have government funding and subsidies without getting rid of private research or patents.
- jahooma 13y agoBut how could it be any other way? Isn't it an inherent gamble to develop drugs since most of the drug-creation attempts are bound to fail? You could just pay researchers to "try" to come up with drugs, regardless of whether they get results, but that doesn't seem like it would work very well. Is there any other way to smooth out the rewards?